New hope for young women with bone loss from missed periods

NCT ID NCT06533865

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding romosozumab to standard estrogen therapy improves bone density in girls and women aged 14-30 who have stopped menstruating due to intense exercise, stress, or an eating disorder. Participants receive either romosozumab or a placebo for 6 months, plus estrogen patches and progesterone pills, followed by one IV dose of zoledronate. The goal is to see if the combination leads to stronger bones compared to placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FHA (FUNCTIONAL HYPOTHALAMIC AMENORRHEA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

functional hypothalamic amenorrhea hypoalphalipoproteinemia, primary, 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Virginia Medical Center

    RECRUITING

    Charlottesville, Virginia, 22903, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact